After a robust third quarter, AstraZeneca Plc confirmed its revenue guidance for the year which is expected to increase by a high single-digit percentage. At the same time, it gave an update on products in late-stage development and a glimpse of new technologies on the horizon. Chief Executive Pascal Soriot outlined the company’s ambitions in a call with journalists on 6 November, which also included comments on new investment in the US.
